Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by DAVID MILLER
Synergistic Activity of the mTOR Inhibitor Ridaforolimus and the Antiandrogen Bicalutamide in Prostate Cancer Models
International Journal of Oncology
Cancer Research
Oncology
Related publications
Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer
Clinical Genitourinary Cancer
Oncology
Urology
Phase I Study of the mTOR Inhibitor Ridaforolimus and the HDAC Inhibitor Vorinostat in Advanced Renal Cell Carcinoma and Other Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
The Antiandrogen Bicalutamide Activates the Androgen Receptor (AR) With a Mutation in Codon 741 Through the Mitogen Activated Protein Kinase (MARK) Pathway in Human Prostate Cancer PC3 Cells
Oncology Reports
Medicine
Cancer Research
Oncology
Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
Prostate Cancer
Cancer Research
Oncology
Urology
Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived From Pancreatic Cancer and Cancer Stem Cells
Molecular Cancer Therapeutics
Cancer Research
Oncology
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Clinical Medicine Insights: Oncology
Oncology
Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer
Oncogenesis
Cancer Research
Molecular Biology
Mp44-02 Effects of Antiandrogen and 5-Alpha-Reductase Inhibitor on Prostate Tissue Androgen Content
Journal of Urology
Urology
PKM2 Under Hypoxic Environment Causes Resistance to mTOR Inhibitor in Human Castration Resistant Prostate Cancer
Oncotarget
Oncology
